Silk Technologies, Ltd.   Report issue

For profit Phase 2
Founded: Plymouth MN United States (2013)

Organization Overview

First Clinical Trial
2019
NCT03889886
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Silk Technologies | Silk Technologies, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

sdp-4 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1